Evaluation of the anti-tumor effects of lactate dehydrogenase inhibitor galloflavin in endometrial cancer cells

Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1

(2013) Marina Vettraino et al.   ANTI-CANCER DRUGS

Inhibition of AMPK and Krebs Cycle Gene Expression Drives Metabolic Remodeling of Pten-Deficient Preneoplastic Thyroid Cells

(2013) V. G. Antico Arciuch et al.   CANCER RESEARCH

Galloflavin prevents the binding of lactate dehydrogenase A to single stranded DNA and inhibits RNA synthesis in cultured cells

(2012) Luigi Fiume et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways

(2012) F. Farabegoli et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Mouse Genetics Suggests Cell-Context Dependency for Myc-Regulated Metabolic Enzymes during Tumorigenesis

(2012) Lisa M. Nilsson et al.   PLoS Genetics

Galloflavin (CAS 568-80-9): A Novel Inhibitor of Lactate Dehydrogenase

(2011) Marcella Manerba et al.   ChemMedChem

Therapeutic targeting of cancer cell metabolism

(2011) Chi V. Dang et al.   JOURNAL OF MOLECULAR MEDICINE-JMM